SLNSW-Maintenance olaparib for patients with newly diag...-TN_cdi_proquest_journals_2604390352

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Full title: Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Author/creator: Banerjee, Susana, Moore, Kathleen N, Colombo, Nicoletta, Scambia, Giovanni, Kim, Byoung-Gie, Oaknin, Ana, Friedlander, Michael, Lisyanskaya, Alla, Floquet, Anne, Leary, Alexandra, Sonke, Gabe S, Gourley, Charlie, Oza, Amit, González-Martín, Antonio, Aghajanian, Carol, Bradley, William H, Holmes, Eileen, Lowe, Elizabeth S, DiSilvestro, Paul.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2604390352

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604390352

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Record identifier

    TN_cdi_proquest_journals_2604390352

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604390352

    Share

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604390352

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Full title

    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    Author / Creator

    Banerjee, Susana ; Moore, Kathleen N ; Colombo, Nicoletta ; Scambia, Giovanni ; Kim, Byoung-Gie ; Oaknin, Ana ; Friedlander, Michael ; Lisyanskaya, Alla ; Floquet, Anne ; Leary, Alexandra ; Sonke, Gabe S ; Gourley, Charlie ; Oza, Amit ; González-Martín, Antonio ; Aghajanian, Carol ; Bradley, William H ; Holmes, Eileen ; Lowe, Elizabeth S ; DiSilvestro, Paul

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2021, Vol.22 (12), p.1721-1731

    Record Identifier

    TN_cdi_proquest_journals_2604390352

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Acute myeloid leukemia Adolescent Adult Adverse events Aged Aged, 80 and over Analysis BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Cancer therapies Care and treatment Chemotherapy Clinical trials Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - genetics Cystadenocarcinoma, Serous - pathology Double-Blind Method Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology Female Follow-Up Studies Genetic aspects Gynecology Humans Leukemia Life expectancy Maintenance Chemotherapy - mortality Middle Aged Mutation Myelodysplastic syndrome Neutropenia Oncology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Patients Phthalazines - therapeutic use Piperazines - therapeutic use Placebos Platinum Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Prognosis Remission Ribose Survival Survival analysis Survival Rate Young Adult

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2604390352

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2604390352

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections